patent.fyi
Applications  /  US 2026/0354359
United States Patent Application Publication

US 2026/0354359 A1

Published
Nov 12, 2026
Filed
Mar 10, 2026
Earliest date on the face
Sep 11, 2023
Classification
A01K 67/0278
First published here
Nov 18, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Primary thymic tissue graft

What ifWhat if a fragment of primary human thymus provides the site of T-cell development?
Claim language“human stem-cell derived thymic organoids”

The graft retains native thymic epithelium and stromal cells. Human hematopoietic progenitors enter the graft and develop into T cells within that tissue.

1.1Ex vivo tissue readout

What ifWhat if the human test tissue stays in culture and encounters T cells collected from the mouse?
Claim language“at least one engrafted human tissue sample”

A human tumor slice sits on a porous culture insert. T cells recovered from the mouse enter the culture, where fluorescence imaging measures tumor-cell death.

1.2Mismatched donor response assay

What ifWhat if the thymic organoid and the test tissue come from donors with different HLA types?
Claim language“the same or are HLA-matched”

HLA typing identifies the differences between the two graft sources. An unstimulated group and a treatment group carry the same donor pairing, and the assay compares T-cell infiltration and tissue injury between the groups.

1.2HLA expression confined to grafts

What ifWhat if the thymic organoid and test tissue share HLA alleles while the mouse carries no human HLA transgene?
Claim language“the humanized mouse is HLA-matched to the sTOs”

Human thymic epithelial cells provide HLA signals during T-cell selection. The human test tissue presents peptides on shared HLA molecules, and the assay measures T-cell activation within that graft.

1.1Transfer of mature T cells

What ifWhat if the mouse receives mature human T cells from the test tissue donor?
Claim language“engrafted human stem-cell derived thymic organoids”

Mature T cells isolated from donor blood enter the circulation of a recipient carrying the donor's tissue graft. The assay measures graft infiltration and T-cell activation over a defined observation period.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Skin contact material testing

A mouse carries a human stem-cell-derived thymic organoid and a full-thickness human skin graft from the same donor or from HLA-matched donors. The mouse expresses the human leukocyte antigen (HLA) alleles used to match the thymic organoid. A removable patch holds a candidate wearable sensor material against the human skin graft, and a matched control mouse receives a patch with the backing alone. Histology measures epidermal injury and human T-cell infiltration beneath each patch.

Component substitution

Engineered skin replaces the skin explant

A reconstructed skin sheet replaces an intact donor skin explant as the human tissue graft. Human dermal fibroblasts populate a collagen matrix, and human keratinocytes form a stratified epidermis on its surface at an air–liquid interface. The skin cells and the stem cells used to make the thymic organoid come from the same donor or from HLA-matched donors. The skin sheet sits epidermis-side up on a dorsal graft bed, and the HLA-matched mouse carries the thymic organoid at a separate site.

Parameter or scale variation

One or two thymic organoid grafts

One cohort receives one stem-cell-derived thymic organoid under the left renal capsule, and a second cohort receives two organoids, one under each renal capsule. Organoids come from the same production batch and have comparable sizes at implantation. Each HLA-matched mouse also carries one human skin graft from the organoid stem-cell donor or an HLA-matched donor. Blood collected at 4, 8, and 12 weeks after implantation provides human T-cell counts for comparison between cohorts.

Combination with existing systems

Perfusion imaging of the skin graft

An HLA-matched mouse carries a stem-cell-derived thymic organoid and a dorsal human skin graft from the same donor or from HLA-matched donors. A laser speckle contrast imaging system records the skin graft and a strip of neighboring mouse skin in the same field of view. The camera uses a fixed working distance, and the imaging stage maintains a consistent surface temperature across sessions. Software calculates the ratio of graft perfusion to neighboring skin perfusion and tracks it over time.

Linked blood and graft receptor profiling

An HLA-matched mouse carries a human stem-cell-derived thymic organoid and a skin graft from the same donor or from HLA-matched donors. A receptor sequencing workflow processes human T cells collected from serial blood samples and from the skin graft at the study endpoint. Each sample receives a molecular index that identifies the mouse, tissue, and collection time. Software groups reads by T-cell receptor beta-chain sequence and reports which groups appear in both blood and graft and how their blood frequencies change over time.

Automated or data-driven variant

Automated counting of graft T cells

An HLA-matched mouse carries a human stem-cell-derived thymic organoid and a skin graft sourced from the same donor or from HLA-matched donors. Skin graft sections receive a nuclear stain and fluorescent labels for human CD3 and epidermal keratins. Image analysis software segments nuclei, assigns CD3 signal to individual cells, and uses the keratin signal to separate epidermis from dermis. The software reports human CD3-positive cells per square millimeter in each compartment and flags fields with poor focus or saturated signal for review.

Specific version of a part

Thymic organoid beneath renal capsule

Human induced pluripotent stem cell derivatives form a three-dimensional aggregate containing thymic epithelial cells. The aggregate sits in a pocket beneath the renal capsule, where nearby vessels supply the graft.

Subcutaneous tumor tissue graft

A small fragment of human tumor sits in a subcutaneous pocket on the flank. The fragment contains tumor cells and associated stroma, and serial caliper measurements track graft growth.

Single donor with matched host

Reprogrammed blood cells from one donor supply the stem cells for the thymic organoid, and a biopsy from the same donor supplies the tissue graft. HLA genotyping identifies shared class I and class II alleles for selection of a recipient mouse that expresses those human alleles.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2013/0273655 A1
Published
Oct 17, 2013
Filed
Mar 12, 2013
Class
C12N 15/113
Document BUS 2021/0123022 A1
Published
Apr 29, 2021
Filed
Jun 12, 2019
Class
C12N 5/0646
Claim 1
Document A
Document B
1.1engrafted human stem-cell derived thymic organoids (sTOs) and at least one engrafted human tissue sample
For human engraftment detection, the iPS—HSC's can be labeled using a lentiviral system along with green fluorescent protein (GFP) as a reporter.
A · US 2013/0273655 A1 · ¶ 51
FIGS. 2A-2D concern generation of human HSC-engineered iNKT cells in a BLT (human bone marrow-liver-thymus engrafted NOD/SCID/γc−/− mice) humanized mouse model.
B · US 2021/0123022 A1 · ¶ 50
1.2wherein a source of the human stem-cells from which the sTOs are derived and a source of the at least one engrafted human tissue sample are the same or are HLA-matched, and the humanized mouse is HLA-matched to the sTOs.
Tissues derived from iPSCs will be a nearly identical match to the cell donor and thus probably avoid rejection by the immune system.
A · US 2013/0273655 A1 · ¶ 16

An empty cell means only that no passage was reproduced there.

Statements in these documents
The present invention provides for increased transplantation success by enhancing the ability of HSC to engraft in the host's hematopoietic niche through increasing, or inhibiting specific microRNAs.
A · US 2013/0273655 A1 · ¶ 3
Also, the present invention is not limited to the hematopoietic stem cell niche (iPS-derived HSCs, cord blood and bone marrow stem cells), and can be extended to a variety of other tissue stem cell niches (e.g., neuronal, pancreatic) to study cellular development and differentiation for future iPS-based cellular therapies.
A · US 2013/0273655 A1 · ¶ 3
Such an approach is costly, manufacture labor intensive, and difficult to broadly deliver to all patients in need.
B · US 2021/0123022 A1 · ¶ 4
The ability to manufacture a therapeutic cell population or a cell population that can be used to create a therapeutic cell population “off-the-shelf” increases the availability and usefulness of new cellular therapies.
B · US 2021/0123022 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0354359 A1, claim 1, first published 2026-11-18T21:55:14-05:00, https://patent.fyi/US20260354359/, SHA-256 3557effd592340db43b0ca09e4fe4dfdc4eee0e95bba44be779115c419dcf715
First published
Permanent addresshttps://patent.fyi/US20260354359/
Content fingerprint (SHA-256)3557effd592340db43b0ca09e4fe4dfdc4eee0e95bba44be779115c419dcf715
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi